Benefits
Blood Pressure Within Normal Range — UC Davis Trials
Two placebo-controlled human clinical trials at UC Davis School of Medicine Department of Preventative Cardiology found MegaNatural-BP supports blood pressure within normal range. Metabolic Syndrome trial showed 12 mmHg systolic / 8 mmHg diastolic reductions; prehypertension trial showed 8 mmHg systolic / 5 mmHg diastolic reductions at 300 mg/day.
Three Placebo-Controlled Human Clinical Trials
Backed by THREE placebo-controlled human clinical trials — distinguishes from many grape seed extracts with weaker evidence.
Endothelial Function Improvement
Improves endothelial function and overall vascular health in multiple RCTs.
Athletic Performance via Blood Flow
9 clinical studies showing improvements in blood flow and athletic performance — relevant pre-workout ingredient for endurance.
Six-Week Onset
Clinical studies show benefits after just 6 weeks — practical timeline for consumer applications.
Patented Hot-Water Extraction
Distinctive manufacturing process produces unique structure and composition vs solvent-extracted generics.
Sustainable California Origin
Made in California from special seed blend from unfermented red and white wine grape seeds — sustainable byproduct upcycling from E. & J. Gallo Winery.
Mechanism of action
Proanthocyanidin (PAC) Vascular Effects
Grape seed proanthocyanidins enhance endothelial nitric oxide synthase (eNOS); improve vasodilation; modest BP effects.
Antioxidant ORAC Activity
>90% proanthocyanidin content provides high ORAC antioxidant capacity; quenches vascular reactive oxygen species.
ACE Inhibition (Modest)
Modest angiotensin-converting enzyme inhibition; relevant to BP effects.
Hot-Water Extraction Distinction
Polyphenolics' patented hot-water process produces specific PAC profile distinct from solvent-extracted alternatives.
Capillary Integrity
PACs support capillary integrity broadly relevant to vascular health.
Clinical trials
Placebo-controlled trial of MegaNatural-BP in metabolic syndrome patients at UC Davis Department of Preventative Cardiology.
Metabolic syndrome patients with elevated BP.
12 mmHg systolic / 8 mmHg diastolic reductions vs placebo. Significant BP reductions.
RCT of MegaNatural-BP 300 mg/day for 2 months in prehypertension patients.
Prehypertensive adults.
8 mmHg systolic / 5 mmHg diastolic reductions vs placebo. Established prehypertension evidence.
RCT in pre- and stage I hypertension at 300 mg/day.
Pre- and stage I hypertensive adults.
Improved ambulatory blood pressure measurements.